2013 – Dr. Howard Feldman

Howard Feldman, MD, FRCP (C) is Professor of Neurology and Executive Associate Dean, Research at the Faculty of Medicine, University of British Columbia, Vancouver. In his research, Dr. Feldman has made seminal contributions to his field with scientific discoveries and clinical research focussed on aging, mild cognitive impairment/ Alzheimer’s disease, frontotemporal dementia (FTD) and diagnostic/therapeutic trials. His research has contributed to the discoveries of the progranulin (Nature 2006) and C9ORF72 (Neuron 2011) genetic mutations which cause FTD and FTD with motor neuron disease as well as to the development of important novel criteria for Alzheimer’s disease (Lancet Neurology 2007, 2011). He has lead a number of international clinical trials in Alzheimer’s disease establishing important and novel data, informing care across the continuum of the disease. His career contributions have been profiled in Lancet Neurology in 2007, and he has been appointed as Fellow of the Canadian Academy of Health Sciences and of the American Academy of Neurology. He has served as inaugural Fisher Family and Alzheimer Society of British Columbia Endowed Professorship for Research in Alzheimer’s Disease. From 2009-2011, he took a leave from his academic appointment at UBC, to take on a senior leadership role as therapeutic area head for neuroscience global clinical research at Bristol-Myers Squibb, where his research focussed on developing novel pharmaceutical therapies for neurodegenerative and other neurological/psychiatric disorders. He returned to UBC in 2012 to continue his academic career with interests in prevention of AD, and advancing novel clinical trials methodologies. As well he currently serves as the Clinical Director UBC Hospital Clinic for Alzheimer’s Disease and Related Disorders.